Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Epistaxis)
7,640 results
  • Lateral Nasal Wall Respiratory Epithelial Adenomatoid Hamartoma (REAH): A Diagnostic Conundrum. [Journal Article]
  • IJIran J Otorhinolaryngol 2018; 30(99):225-229
  • Goh LC, Wan MH, … Elangkumaran S
  • CONCLUSIONS: This case demonstrates the rare presentation of a REAH, which had arisen from the lateral nasal wall. Clinically, it is difficult to distinguish a REAH from a more notorious mass such as a sinonasal malignancy. Therefore, biopsy is mandatory in all cases of lateral nasal mass in order to rule out malignancy before confirming nasal REAH. Fortunately, as seen in this case, a lateral nasal REAH, once diagnosed, can be safely and easily removed from the lateral nasal wall using electrocautery with good surgical outcomes and a low rate of recurrence.
  • Correlating regional emergency epistaxis visits with internet search activity. [Journal Article]
  • AJAm J Otolaryngol 2018 Jul 19
  • Griffith S, Archbold R, Schell S
  • CONCLUSIONS: Search engine activities for the term "nosebleed" correlates strongly with epistaxis-related ED visits. This study demonstrates the usefulness of utilizing Google Trends search data to assess regional disease burdens, which may provide a means for epidemiological study that is quicker than conventional methods.
  • Risk of Major Bleeding with Ibrutinib. [Journal Article]
  • CLClin Lymphoma Myeloma Leuk 2018 Aug 01
  • Mock J, Kunk PR, … Maitland H
  • CONCLUSIONS: The results of the present study have demonstrated a greater rate of major bleeding with ibrutinib use in a standard clinical setting than previously reported. Patients with anemia or an elevated international normalized ratio or requiring anticoagulant and/or antiplatelet medications during ibrutinib therapy have a significantly increased risk of major bleeding. Careful consideration of the risks and benefits for this population is needed. The combination of antiplatelet and anticoagulation medications with ibrutinib therapy is of particular concern.
  • Management of epistaxis in patients with ventricular assist device: a retrospective review. [Journal Article]
  • JOJ Otolaryngol Head Neck Surg 2018 Aug 02; 47(1):48
  • Brown CS, Abi-Hachem R, Jang DW
  • CONCLUSIONS: While these patients are at risk for recurrent spontaneous epistaxis, nonsurgical treatment without active correction of INR or AvWS was largely successful. Placement of hemostatic material, as opposed to cautery with silver nitrate, should be considered as a first-line treatment in this group. Multidisciplinary collaboration is critical for successful management.
New Search Next